Zelira Therapeutics to go head-to-head with big pharma in US clinical pain trial
The medicines developer has locked down a key approval to test its own offering against a multi-billion-dollar drug in a 12-week observational study into neuropathic pain. Zelira will test its proprietary product in a neuropathic pain study in the US.
Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZALDF) has secured Institutional Review Board (IRB) approval for a pain observational trial to take place in the US.
The cannabinoid medicines developer is set to test its patent-protected product against a big pharmaceutical company’s multi-billion-dollar revenue drug.
Approval from IRB means Zelira has navigated a regulatory approval path for the upcoming trial, with the first batch of results expected in 2022’s first half.
International Rising Stars: 9 Cannabis CEOs To Keep An Eye On
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
International Rising Stars: 9 Cannabis CEOs To Keep An Eye On
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.